MX2021003516A - Compuesto de aminopirimidina. - Google Patents

Compuesto de aminopirimidina.

Info

Publication number
MX2021003516A
MX2021003516A MX2021003516A MX2021003516A MX2021003516A MX 2021003516 A MX2021003516 A MX 2021003516A MX 2021003516 A MX2021003516 A MX 2021003516A MX 2021003516 A MX2021003516 A MX 2021003516A MX 2021003516 A MX2021003516 A MX 2021003516A
Authority
MX
Mexico
Prior art keywords
present
compound
aminopyrimidine compound
prophylaxis
symbol
Prior art date
Application number
MX2021003516A
Other languages
English (en)
Inventor
Junya Shirai
Tomohiro Okawa
Akito Shibuya
Zenyu Shiokawa
Malcolm Maccoss
Yasufumi Miyamoto
Nobuyuki Matsunaga
Takashi Nakahata
Original Assignee
Cardurion Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Llc filed Critical Cardurion Pharmaceuticals Llc
Publication of MX2021003516A publication Critical patent/MX2021003516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto que tiene una acción inhibidora de CaMKII, que se espera que sea útil como agente para la profilaxis o el tratamiento de enfermedades cardíacas (particularmente taquicardia ventricular polimórfica catecolaminérgica, fibrilación auricular posoperatoria, insuficiencia cardíaca, arritmia fatal) y similares. La presente invención se refiere a un compuesto representado por la fórmula (I): (ver Fórmula) en donde cada símbolo es como se define en la descripción, o una sal del mismo.
MX2021003516A 2018-09-25 2019-09-24 Compuesto de aminopirimidina. MX2021003516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862735897P 2018-09-25 2018-09-25
PCT/US2019/052730 WO2020068854A1 (en) 2018-09-25 2019-09-24 Aminopyrimidine compound

Publications (1)

Publication Number Publication Date
MX2021003516A true MX2021003516A (es) 2021-05-27

Family

ID=69885308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003516A MX2021003516A (es) 2018-09-25 2019-09-24 Compuesto de aminopirimidina.

Country Status (11)

Country Link
US (2) US11130752B2 (es)
EP (1) EP3856188B1 (es)
JP (1) JP7447098B2 (es)
KR (1) KR20210082454A (es)
CN (1) CN113365632B (es)
AU (1) AU2019350717A1 (es)
CA (1) CA3114198A1 (es)
IL (1) IL281765B2 (es)
MX (1) MX2021003516A (es)
TW (1) TW202035375A (es)
WO (1) WO2020068854A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001227A (es) 2000-08-08 2004-09-10 Johnson & Johnson Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.
ATE415396T1 (de) 2000-09-20 2008-12-15 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
AU2004261484A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
JP2007504229A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
JP2009514876A (ja) 2005-11-03 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼのための化合物および組成物
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
PT2200436E (pt) * 2007-09-04 2015-04-29 Scripps Research Inst Pirimidinilaminas substituídas como inibidoras da proteína quinase
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
CN103298794A (zh) 2010-11-09 2013-09-11 塞尔卓姆有限公司 作为tyk2抑制剂的吡啶化合物及其氮杂类似物
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013146963A1 (ja) 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
PT2840080T (pt) 2012-04-17 2018-02-06 Fujifilm Corp Composto heterocíclico que contém azoto ou sal do mesmo
CN104271569B (zh) 2012-05-03 2016-08-24 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
US10087186B2 (en) 2014-01-29 2018-10-02 Glaxosmithkline Intellectual Property Development Limited Compounds as LRRK2 kinase inhibitors
NO2721710T3 (es) 2014-08-21 2018-03-31
US10988482B2 (en) 2015-08-13 2021-04-27 Beijing Hanmi Pharmaceutical Co., Ltd. IRAK4 inhibitor and use thereof
EP3600327A4 (en) * 2017-03-27 2020-10-28 Cardurion Pharmaceuticals, LLC HETEROCYCLIC COMPOUND
WO2020068846A1 (en) 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound

Also Published As

Publication number Publication date
IL281765A (en) 2021-05-31
US20200095240A1 (en) 2020-03-26
IL281765B1 (en) 2023-12-01
KR20210082454A (ko) 2021-07-05
IL281765B2 (en) 2024-04-01
EP3856188B1 (en) 2023-06-21
WO2020068854A1 (en) 2020-04-02
CN113365632B (zh) 2024-03-08
JP7447098B2 (ja) 2024-03-11
JP2022502391A (ja) 2022-01-11
TW202035375A (zh) 2020-10-01
CA3114198A1 (en) 2020-04-02
AU2019350717A1 (en) 2021-05-27
EP3856188A4 (en) 2022-02-23
US20220112184A1 (en) 2022-04-14
EP3856188A1 (en) 2021-08-04
US11130752B2 (en) 2021-09-28
CN113365632A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
EP4234017A3 (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
CO2023005189A2 (es) Compuestos de heteroarilo fusionado y su uso como inhibidores de camkii
MX2022014414A (es) Compuestos de pirimidinodiona contra estados cardiacos.
CA3045762A1 (en) Cyclic dinucleotides as sting (stimulator of interferon genes) agonists
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
PH12017502363A1 (en) Brk inhibitory compound
MX2021009378A (es) Derivados de pirazolopirimidina como inhibidor de cinasa.
MX2018002889A (es) Compuesto de pirimidina fusionada o sal del mismo.
MX2008001386A (es) Agente terapeutico para diabetes.
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
MX2019011783A (es) Inhibidores de ip6k.
WO2015073922A3 (en) Inhibition of oxidative stress in atrial fibrillation
BR112018013033A2 (pt) compostos de indolinonas e seu uso no tratamentod de doenças fibróticas
GEP20217332B (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX2021003516A (es) Compuesto de aminopirimidina.
WO2016023028A3 (en) G protein-coupled receptor kinase 2 inhibitors and methods for use of the same
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MY197042A (en) Compounds
FI3805243T3 (fi) Androstaanijohdannaisia, joilla on aktiivisuus puhtaina tai pääasiallisesti puhtaina SERCA2a:n stimulaattoreina, sydämen vajaatoiminnan hoitoon
EP4123017A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF ISCHEMIC DISEASES COMPRISING CARDIAC STEM CELLS
MX2019012808A (es) Compuesto heterociclico.
WO2019227056A3 (en) Methods and compositions involving bucindolol for the treatment of atrial fibrillation
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
MX2019012810A (es) Compuesto heterociclico.